CBD Oil For Anxiety Relief https://zenhemp.net Fri, 25 Sep 2020 19:14:15 +0000 en-US hourly 1 https://wordpress.org/?v=5.5.1 CBD For Gallbladder: What Does The Science Say? – Cannabis Herald https://zenhemp.net/cbd-for-gallbladder-what-does-the-science-say-cannabis-herald/?utm_source=rss&utm_medium=rss&utm_campaign=cbd-for-gallbladder-what-does-the-science-say-cannabis-herald Fri, 25 Sep 2020 19:14:15 +0000 http://CBMiTWh0dHBzOi8vY2FubmFiaXNoZXJhbGQuY28vY2JkLWZvci1nYWxsYmxhZGRlci13aGF0LWRvZXMtdGhlLXNjaWVuY2Utc2F5LzIxNjYv0gEA Glaucoma is one of the leading causes of blindness in the US. According to the Global Burden of Diseases study 2010, nearly 2.1 million people were blind while 4.2 million were visually impaired due to Glaucoma. These numbers were projected to increase widely over the next couple of decades. This […]

The post CBD For Gallbladder: What Does The Science Say? – Cannabis Herald appeared first on CBD Oil For Anxiety Relief.

]]>

Glaucoma is one of the leading causes of blindness in the US. According to the Global Burden of Diseases study 2010, nearly 2.1 million people were blind while 4.2 million were visually impaired due to Glaucoma. These numbers were projected to increase widely over the next couple of decades.

This eye condition occurs due to the damage to the optic nerve. The most common reason for glaucoma is fluid build-up in the front part of the eye. This fluid build-up increases pressure on the eye, damaging the optic nerve, and results in permanent damage to the vision.

Glaucoma can occur at any age but is common in adults over the age of 40. This condition can lead to permanent vision loss.

What we know about CBD and Glaucoma?

The role of CBD in reducing or treating Glaucoma is unclear. With conflicting research and studies showing different results, further clinical trials will help establish the role of CBD for glaucoma.

Let us first understand glaucoma and its effects on the patients suffering from the condition.

As mentioned earlier, glaucoma occurs due to damaged optic nerves. The optic nerve is the most essential organ responsible for vision. It works by sending signals to the brain in the form of images.

When the pressure in your eye, also known as the intraocular pressure, increases because of fluid build-up, it starts affecting the optic nerve.

This nerve damage results in vision problems as it can no longer send signals to the brain. When this damage worsens, you will experience permanent blindness.

Glaucoma doesn’t show any signs in the early stages. This makes it difficult to detect and treat at the correct time. Unless you visit an ophthalmologist for regular check-ups, you won’t be able to identify this condition.

By the time the symptoms start showing, deterioration sets in. Ultimately, this condition results in permanent blindness.

Medications are available to lower intraocular pressure. But they can cause intolerable side effects such as burning, blurred vision, and tearing. Long term use can also reduce the efficacy of these drugs.

A study by the British Journal of Ophthalmology states that “..different cannabinoids, including cannabidiol, cannabigerol, endogenous cannabinoids, and some synthetic cannabinoids, can reduce the IOP when administered systemically and topically.” This feature along with cannabinoids’ neuroprotective properties can make CBD a good agent to treat Glaucoma.

The hemp plant contains over a hundred different cannabinoids, flavonoids, and terpenes. These compounds are responsible for most of the therapeutic properties of the hemp plant. Among the various cannabinoids, THC and CBD are of chief interest.

In 1971, a study on a small number of subjects conducted by Helper and Frank showed that smoking marijuana lowered the Intraocular Pressure or IOP by about 25 to 30%. The effect lasted for about 3 to 4 hours. The subjects reported side effects such as lesser tear production, changes in pupil size, tachycardia, etc.

Long term use of smoking marijuana has the possibility of developing tolerance. The reduction of the intraocular pressure seemed to be inversely related to the duration of marijuana smoking.

On the contrary, another study conducted by Dawson et al showed that marijuana users of 10 years or more and non-users showed a similar reduction in IOP after marijuana treatment.

Studies like the one published in the Journal of Ocular Pharmacology and Therapeutics show that cannabinoids like CBD and CBN were able to reduce the IOP.

Smoking cannabis can be unhealthy due to its various side effects. Therefore scientists have started looking for other safer and effective methods for administering CBD to reducing IOP, thus reducing the effects of Glaucoma.

Oral Administration of CBD for IOP in Glaucoma:

A study published in the Journal of Glaucoma studied the effects of oral administration of low doses of CBD and THC on intraocular pressure.

The findings were as follows:

  • A single dosage of 5mg of THC could reduce the pressure temporarily. Most of the patients showed good levels of tolerance to the dosage.
  • While the sublingual administration of 20mg CBD didn’t reduce IOP, a 40 mg dosage was able to slightly reduce the IOP.

Topical Administration of CBD for IOP in Glaucoma:

Topical application is one of the safer methods of administering CBD to maximize the results and minimize the side effects. Scientists applied the same principle to observe the effectiveness of CBD in reducing IOP in the form of eye drops.

One problem they encountered while conducting the experiments was that the cannabinoid extracts were lipophilic making them difficult to dissolve in water. As a result, administering them in the form of eye drops proved to be a challenge.

Since the surface of the eye is constantly moist due to tears, water solubility is extremely important for the eye drops to be effective.

With the administration of any eye drops, much of the solution goes waste due to lacrimal drainage.  As a result, only about 5% of the dose reaches the intraocular tissue.

These factors were a challenge for scientists trying to test the topical administration of cannabinoids for glaucoma.

A study by Keith Green and Walter.M.Jay published in JAMA Ophthalmology employed 28 male volunteers who were administered THC that used mineral oil as the solvent. Most of these volunteers experienced side effects such as eye irritation, burning sensation, and swelling in the eyelids.

According to the studies published in the Journal of Current Eye Research and the Life Sciences journal, cyclodextrin, methylcellulose, and polyvinyl alcohol improve the aqua-solubility of cannabinoids, making them the best carriers for oral administration of CBD.

This study provides value for scientists and researchers working on the IOP-reducing properties of CBD through topical administration.

Neuroprotective properties of CBD for Glaucoma:

In Glaucoma, reducing the intraocular pressure by itself may not be enough to prevent vision loss.

A study on the neuroprotective effect of THC and CBD published in The American Journal of Pathology details the role of glutamate-induced neurotoxicity in glaucoma.

Glutamate is an important neurotransmitter. It is present in high concentrations in the retinal cells or the retinal ganglion cells. Certain conditions can cause glutamate to release in higher amounts. This excess release leads to the death of the retinal ganglion cells which in turn contributes to glaucoma.

The study explains the role of glutamate in causing the death of the retinal neurons due to the excess formation of peroxynitrite. THC and CBD may reduce the formation of peroxynitrite, thereby protecting the retinal neurons and the ganglion cells.

The neuroprotective properties of THC and CBD play a significant role in reducing the excess formation of glutamate. This happens due to the activation of the CB1 receptor which is a part of the body’s endocannabinoid system or ECS.

The ECS including the endocannabinoids and its receptors is present in the ocular tissues and the retina. The endocannabinoids are present throughout the eyes, the only exception being the lens.  

The ECS system is responsible for maintaining various systems of the human body. The endocannabinoids and receptors together form a network with each of them being responsible for one or more systems and functions.

Through this network, the ECS system is responsible for maintaining coordination between various processes and systems for smooth body metabolism. In other words, the ECS system maintains homeostasis.

A disturbance in this homeostasis, usually due to an injury or inflammation, can disturb the endocannabinoid system and its functioning.

In such situations, other receptors and pathways may initiate the process of protecting the nerve cells from death.

By therapeutically modifying the ECS system, it may be possible to reduce nerve death, thereby improving the symptoms that occur due to glaucoma.

The neuroprotective properties of CBD in combination with its anti-inflammatory and antioxidant properties can make it an ideal candidate to curb the neuron damage and neuron death in glaucoma.

The THC cannabinoid can activate the CB1 and CB2 within the ECS system to trigger the neuroprotective properties, and thus may provide relief from glaucoma symptoms that occur due to cell death, and also restore vision to some extent.

Since THC is associated with certain unwanted symptoms, and due to its psychoactive effects, the therapeutic properties of CBD as a neuroprotective agent are under focus.

The neuroprotective properties of CBD may be due to its ability to activate certain signaling pathways. Besides, CBD also attached itself to the CB2 receptors which then triggers the neuroprotective properties, preventing nerve damage and death.

Both THC and CBD have shown protective action against retinal injury, strengthening their position as possible therapeutic candidates for Glaucoma.

Along with its neuroprotective properties, CBD also inhibits the degradation of certain cannabinoids that act as neuroprotectants. THC may play an additional role in activating certain neuroprotective pathways.

Antioxidant properties of CBD

We already know that elevated glutamate levels act as one of the risk factors for Glaucoma by initiating the death of the ganglion cells and nerves. In vivo and in vitro studies have shown that such nerve death can be reduced with the presence of antioxidants.

Antioxidants work by reducing the production of peroxynitrite, the factor that is chiefly responsible for triggering the cell and nerve death.

CBD and THC have both shown potent antioxidant properties by protecting nerves from glutamate-induced death and oxidative stress as well.

Despite the growing evidence of CBD as an ideal therapeutic candidate for treating glaucoma, certain factors still put it in a jeopardy.

In most cases, CBD may not be able to act alone to deliver therapeutic properties such as lowering the intraocular pressure, protecting the nerves, and rendering its antioxidant properties.

There is still conflicting research if CBD will be able to act alone or will need THC as its partner to be able to render all the properties.

Since it attaches itself to the CB1 receptors, THC displays certain psychoactive properties which may cause unwanted side effects with regular use.

Another study shows that CBD in higher amounts, when paired with THC can counter the unwanted THC’s side effects while retaining the therapeutic properties of both the compounds.

While this factor may pose some hope for THC and CBD as possible glaucoma therapy agents, further research will be necessary to arrive at a concrete conclusion.

CBD for treating the symptoms of Glaucoma:

Glaucoma is a serious eye condition marked by nerve damage and subsequent vision loss. The condition starts with fluid build up behind the eye.

Under normal conditions, the eye has the presence of fluid called aqueous humor. This fluid usually drains out through a mesh-like channel. In some cases, this mesh-like channel gets blocked and with no outlet, the fluid starts building up in the eye.

This fluid build-up increases pressure on the optic nerve which is responsible for sending image signals to the brain. With the resultant pressure, the optic nerve starts getting damaged and you can sense a lessening vision.

A completely damaged optic nerve results in total vision loss. Usually, once the reduction in vision starts, deterioration is quite quick, giving you little or no time to consult an ophthalmologist for treatment.

While this condition is most commonly seen in adults over 40, it can occur in people of any age group, including infants and children. This condition can be inherited, meaning it runs in families.

Conditions such as diabetes, high blood pressure, heart disease, etc can result in glaucoma. Also, certain medications increase the risk factors for getting glaucoma.

Sometimes an injury in one or both the eyes can cause glaucoma in the long run. If you have thinner corneas or suffer from eye pressure, you may be at risk of getting glaucoma at some point.

Symptoms of Glaucoma:

To understand the symptoms of glaucoma, we must first understand the types of this condition.

Glaucoma is categorized into four types for a general understanding, though there may be even more types from a medical or therapeutic point of view.

Open-Angle Glaucoma:

This is the most commonly occurring form of glaucoma and is also known as wide-angle glaucoma. The drainage angle remains open, but the mesh is partially blocked, resulting in gradual pressure build-up. This glaucoma takes a long time to completely block your vision.

This glaucoma type doesn’t cause any pain to the eye. You will not notice any vision changes in the initial stages. Regular eye check-ups are crucial to detect and treat the condition early

Symptoms include:

  • Blind spots and patches in the central and peripheral visions in one or both the eyes.
  • Tunnel vision occurs in advanced stages.

Angle-closure Glaucoma:

This condition is also known as chronic angle-closure or narrow-angle glaucoma. As the name suggests, the drain angle or the space between the iris and the cornea becomes too narrow. This blocks the fluid from draining out. This results in a sudden build-up in your eye.

Angle-closure glaucoma is sometimes linked to far-sightedness or cataracts. It is marked by the clouding of the lens in the eye.

Symptoms include:

  • The appearance of halos around lights
  • Severe headache
  • Nausea and vomitings
  • Blurred vision.
  • Eye pain
  • Eye redness
  • Blurred vision

Normal-Tension Glaucoma:

Some doctors consider this as a form of open-angle glaucoma. With this condition, the eye pressure remains normal to average, but can still cause damage to the optic nerve.

While the exact causes of this kind of Glaucoma are not known, symptoms include the appearance of blind spots in the vision.

Pigmentary Glaucoma:

Pigments from the iris block the drain channels resulting in a pressure build-up on the optic nerve.

Symptoms include:

  • Difficulty with side vision
  • Rarely, the appearance of haloes or blurry vision.

Some of the more significant causes of glaucoma such as pressure build-up and nerve damage may be treated with the pressure reducing and the neuroprotective and the antioxidant properties of CBD. These symptoms can include blurry vision, the appearance of halos around light, etc.

Let us look at the role of CBD in treating the common symptoms of CBD which include:

  • Eye pain. 
  • Headaches.
  • Nausea.
  • Vomitings.

CBD for Eye Pain and Headaches:

CBD has analgesic and anti-inflammatory properties. A study published in Cannabis and Cannabinoid research also states CBD and THC may reduce corneal pain.

According to the same study, THC may reduce pain and inflammation by binding with the CB1 and CB2 receptors. CBD may activate the non-cannabinoid receptors for a reduction in pain and inflammation.

With these properties, CBD and THC may provide relief from symptoms such as redness in the eye, eye pain, and headaches.

CBD for Nausea and Vomitings:

CBD has antiemetic properties. It can suppress nausea and vomitings within a limited dose range according to a study “Regulation of Nausea and Vomitings by Cannabinoids

With its pressure reducing, neuroprotective, analgesic, anti-inflammatory, and antiemetic properties, CBD may provide relief and to a certain extent treat glaucoma.

Consulting an experienced ophthalmologist who has expertise in CBD is crucial before starting CBD for glaucoma, as you must consider multiple aspects before starting this alternative line of medications.

The presence of THC may prove a hurdle in certain cases. The presence of this cannabinoid along with CBD can prove more effective to treat Glaucoma, than CBD acting alone.

Also, the effectiveness of THC/CBD as compared to the dosages still needs to be established. Further studies are needed to establish the safety of THC to treat Glaucoma when compared with the risk factors.

To sum up, CBD may be effective to treat Glaucoma and its various symptoms. Further investigations and clinical trials will help strengthen the theory.

Source: https://cannabisherald.co/cbd-for-gallbladder-what-does-the-science-say/2166/

The post CBD For Gallbladder: What Does The Science Say? – Cannabis Herald appeared first on CBD Oil For Anxiety Relief.

]]>
Medical Cannabis 2019 – Global Sales, Price, Revenue, Gross Margin and Market Share Forecast Report – EIN News https://zenhemp.net/medical-cannabis-2019-global-sales-price-revenue-gross-margin-and-market-share-forecast-report-ein-news/?utm_source=rss&utm_medium=rss&utm_campaign=medical-cannabis-2019-global-sales-price-revenue-gross-margin-and-market-share-forecast-report-ein-news Fri, 25 Sep 2020 18:24:11 +0000 http://CBMiiAFodHRwczovL3d3dy5laW5uZXdzLmNvbS9wcl9uZXdzLzUyNzAyNjM3MC9tZWRpY2FsLWNhbm5hYmlzLTIwMTktZ2xvYmFsLXNhbGVzLXByaWNlLXJldmVudWUtZ3Jvc3MtbWFyZ2luLWFuZC1tYXJrZXQtc2hhcmUtZm9yZWNhc3QtcmVwb3J00gEA PUNE, INDIA, INDIA, September 25, 2020 /EINPresswire.com/ —   Medical Cannabis Market – 2019-2025 Report Description: Medicinal cannabis are also known as Medical marijuana, which area used either to treat disease or to improve their symptoms. The two cannabinoids – delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) are used in treatment of […]

The post Medical Cannabis 2019 – Global Sales, Price, Revenue, Gross Margin and Market Share Forecast Report – EIN News appeared first on CBD Oil For Anxiety Relief.

]]>
PUNE, INDIA, INDIA, September 25, 2020 /EINPresswire.com/ —  

Medical Cannabis Market – 2019-2025

Report Description:

Medicinal cannabis are also known as Medical marijuana, which area used either to treat disease or to improve their symptoms. The two cannabinoids – delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) are used in treatment of certain disease or health conditions such as pain, blood pressure, memory, concentration, appetite, sensory stimulus, muscular problems, and seizures.

Save Free Sample Report >> 

https://www.wiseguyreports.com/sample-request/4474287-global-medical-cannabis-market-professional-survey-report-2019

The key players covered in this study
BOL Pharma
Tilray
Medreleaf Corporation
Aurora Cannabis, Inc
Canopy Growth Corporation
Insys Therapeutics, Inc
Aphria, Inc
MGC Pharmaceuticals Limited
GW Pharmaceuticals, plc
Medical Marijuana Inc

The various economies are involved in the activities to legalize the export of medicinal cannabis product, which in turn is expected to fuel growth of the medical cannabis market.

View Complete Report »    

https://www.wiseguyreports.com/reports/4474287-global-medical-cannabis-market-professional-survey-report-2019

Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.

Table of Content:

1 Study Coverage

2 Executive Summary 

3 Breakdown Data by Manufacturers 

4 Breakdown Data by Type 

5 Breakdown Data by Application 

11 Company Profiles 

12 Future Forecast 

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 

14 Value Chain and Sales Channels Analysis 

15 Research Findings and Conclusion

16 Appendix 

Continued …

 About Us:

“Wise Guy Reports Is Part Of The Wise Guy Consultants Pvt. Ltd. And Offers Premium Progressive Statistical Surveying, Market Research Reports, Analysis & Forecast Data For Industries And Governments Around The Globe. Wise Guy Reports Features An Exhaustive List Of Market Research Reports From Hundreds Of Publishers Worldwide. We Boast A Database Spanning Virtually Every Market Category And An Even More Comprehensive Collection Of Market Research Reports Under These Categories And Sub-Categories”.

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

Sales@Wiseguyreports.Com

Http://Www.Wiseguyreports.Com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

NORAH TRENT
Wise Guy Reports
+162 825 80070
email us here

Source: https://www.einnews.com/pr_news/527026370/medical-cannabis-2019-global-sales-price-revenue-gross-margin-and-market-share-forecast-report

The post Medical Cannabis 2019 – Global Sales, Price, Revenue, Gross Margin and Market Share Forecast Report – EIN News appeared first on CBD Oil For Anxiety Relief.

]]>
Checking in on Cannabis Stocks Around the World – Schaeffers Research https://zenhemp.net/checking-in-on-cannabis-stocks-around-the-world-schaeffers-research/?utm_source=rss&utm_medium=rss&utm_campaign=checking-in-on-cannabis-stocks-around-the-world-schaeffers-research Fri, 25 Sep 2020 17:54:22 +0000 http://CBMiamh0dHBzOi8vd3d3LnNjaGFlZmZlcnNyZXNlYXJjaC5jb20vY29udGVudC9uZXdzLzIwMjAvMDkvMjUvY2hlY2tpbmctaW4tb24tY2FubmFiaXMtc3RvY2tzLWFyb3VuZC10aGUtd29ybGTSAQA 5 states could add $9B to the cannabis industry in November Welcome back to our new weekly series, Schaeffer’s Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week and we will look ahead at the pot stocks to watch in the upcoming […]

The post Checking in on Cannabis Stocks Around the World – Schaeffers Research appeared first on CBD Oil For Anxiety Relief.

]]>
Cannabis Pot stock news and analysis

5 states could add $9B to the cannabis industry in November

Welcome back to our new weekly series, Schaeffer’s Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week and we will look ahead at the pot stocks to watch in the upcoming week.

Investor interest in the cannabis industry continues to grow and the leading players continue to break through legal barrier after legal barrier. Right now, nine states and D.C. have legalized recreational marijuana and 29 states have legalized medicinal marijuana. Normally, when we talk “cannabis stocks,” we are talking about companies that sell both recreational and medicinal cannabis. More and more companies, though, are starting to see the opportunity presenting in this quickly growing industry and we are continuing to see more marijuana IPOs on the calendar.

Here’s a quick roundup of the cannabis sector news this week (September 21 through September 25):

Akerna Corp. (NASDAQ:KERN), developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology named MJ Platform, reported financial results for its fiscal fourth quarter as we mentioned last week on Thursday, September 24. Here is a full recording and transcript of the earnings call featuring Jessica Billingsley, CEO of Akerna Corp. The revenue results reported were down 17% year-over-year at about $3 million for the reported quarter. In conjunction with their earnings announcement, Akerna also released an eBook detailing the cannabis industry’s technology needs. Click here to check out the eBook published by Akerna and titled Technology in the Cannabis Industry.

Aurora Cannabis Inc. (NYSE: ACB — $6.53), the Canadian company defining the future of cannabinoids worldwide, also conducted their conference call on September 22 to cover the revenue results for its fiscal fourth quarter. The results were that revenue totaled $72.1 million for the quarter which is a 5% decrease quarter-over-quarter. That level of decrease in earnings has moved ACB stock down more than 20%. On the call, Aurora announced a fiscal full-year net loss of $2.48 billion, and stated that the company had lost its top spot in the consumer marijuana sales north of the U.S. border.

Greenlane Holdings, Inc. (NASDAQ:GNLN), one of the largest worldwide sellers of premium cannabis accessories and specialty vaporization products, announced a new major player on their leadership team on September 21. Greenlane hired Michael Cellucci, a proven leader in tobacco CPG (consumer packaged goods), as the company’s new President of Sales and Marketing for North America. The company also hired Michael Ouwendijk, another proven leader in the tobacco industry, Sales & Marketing Director for Europe.

GW Pharmaceuticals plc. (NASDAQ:GWPH), a UK-based 
biopharmaceutical company, confirmed on September 23 that TGA (Australian Therapeutic Goods Administratio) has officially authorized their CBD medicine to be used in the treatment of Lennox- Gastaut Syndrome (LGS) or Dravet Syndrome patients of two years or older. The company’s CBD medication, Epidyolex, was the first FDA-approved CBD medicine for the treatment of childhood epilepsy. Click here for our coverage on GWPH stock analysis after recent analyst rating adjustments.

On September 21, Therapix Biosciences Ltd. (NASDAQ:TRPX) delisted their stock on NASDAQ. The company had already suspended trading of their stocks since July 2 of this year so this announcement was of no surprise to Wall Street.

Tilray Inc (NASDAQ:TLRY) announced on September 22 that its president and CEO, Brendan Kennedy, sold 500,000 shares of TLRY stock at an average price of $5.13. This was following his sale of another 500,000 shares of TLRY stock on the day before at an approximate price of $5.01. Since his last major sale of stock, Tilray’s stock price has dropped 7.41%.

One of the leading, most highly trusted, and most recognized cannabidiol (CBD) brands, cbdMD, Inc. (NYSE:YCBD) announced on September 24 that, in conjunction with the Natural Products Association (NPA), the company intends to provide additional transparency into the current landscape for investors. As such, cbdMD is launching an invitation-only virtual investor conference entitled “Regulatory Roadmap For The CBD Industry,” which will focus on discussing the current regulatory climate in the CBD industry. It is worth noting that cbdMD was able to grow revenue by 411% over the past year, bringing the total to $40 million in revenue.

Village Farms International, Inc. (NASDAQ:VFF) made an announcement on Thursday, September 24 that the company’s recently launched vape and oil products are now available to consumers in the three most populated provinces in Canada (Ontario, Alberta, and British Columbia) to which Pure Sunfarms distributes. Pure Sunfarms, majority-owned by Village Farms, has announced it’s plans to launch these vape and oil products in additional provinces in coming months, as well as plans to continue expansion of its Cannabis 2.0 products.

A small analyst price target update for Canopy Growth Corp. (NYSE:CGC) could put the company into an ever better position to exceed revenue expectations for the third quarter. Cantor Fitzgerald kept the “neutral” rating for CGC stock, but raised the price by $0.37 to $20.93. Canopy is a Canada-based producer, distributor, and seller of a variety of cannabis and hemp-based products for both medical and recreational usage.

All eyes (for cannabis sector investors, at least) are on legalization efforts at the national and state levels. The delay in the U.S. House of Representatives voting on a bill to legalize cannabis nationwide, there is still significant growth potential on a state level as more states are putting legalization on the ballots. According to New Frontier Data’s most recent report on the cannabis market, there are five state ballot measures this year including in Arizona, Mississippi, Montana, New Jersey, and South Dakota. If all five of these state legalization measures are approved by voters, even without nationwide legalization, the cannabis market stands to grow by an additional $9 billion.

A breakdown of legalization on a state level in the U.S.(SOURCE: Yahoo! Finance)

There are no notable earnings announcements expected in the cannabis arena at this time for next week. 

Source: https://www.schaeffersresearch.com/content/news/2020/09/25/checking-in-on-cannabis-stocks-around-the-world

The post Checking in on Cannabis Stocks Around the World – Schaeffers Research appeared first on CBD Oil For Anxiety Relief.

]]>
Cloud 9 Switzerland Group: nutraceuticals and pharmaceuticals – Health Europa https://zenhemp.net/cloud-9-switzerland-group-nutraceuticals-and-pharmaceuticals-health-europa/?utm_source=rss&utm_medium=rss&utm_campaign=cloud-9-switzerland-group-nutraceuticals-and-pharmaceuticals-health-europa Fri, 25 Sep 2020 17:44:13 +0000 http://CBMiYGh0dHBzOi8vd3d3LmhlYWx0aGV1cm9wYS5ldS9jbG91ZC05LXN3aXR6ZXJsYW5kLWdyb3VwLW51dHJhY2V1dGljYWxzLWFuZC1waGFybWFjZXV0aWNhbHMvMTAzMDA0L9IBAA iStock-OpenRangeStock Life sciences company Cloud 9 Switzerland prioritises patient wellbeing, product quality and innovation in clinical practice. Cloud 9 Switzerland is a life sciences company offering both premium hemp nutraceuticals for the wellness market and pharmaceuticals for the medical market, developing therapies for glaucoma, asthma, and pain using cannabis and […]

The post Cloud 9 Switzerland Group: nutraceuticals and pharmaceuticals – Health Europa appeared first on CBD Oil For Anxiety Relief.

]]>
Cloud 9 Switzerland Group: nutraceuticals and pharmaceuticals
iStock-OpenRangeStock

Life sciences company Cloud 9 Switzerland prioritises patient wellbeing, product quality and innovation in clinical practice.

Cloud 9 Switzerland is a life sciences company offering both premium hemp nutraceuticals for the wellness market and pharmaceuticals for the medical market, developing therapies for glaucoma, asthma, and pain using cannabis and other medicinal plants.

Core to our philosophy is to harness the positive virtues of medicinal plants to provide a healthy balanced lifestyle and improved quality of life for our patients and consumers. We put the wellbeing and health of consumers and patients at the centre of our business strategy and cater to their needs with innovative first mover consumer packaged goods and medicines for specific health disorders.

The company is distributing in Italy and is now developing in Switzerland, Australia, Jamaica and the USA.

Origins

Our headquarters are based in Lugano, Switzerland; and we have subsidiaries in Jamaica, France and sales representation in California, USA. The team behind the company is made up of professionals coming from multi-national food and beverage, flavours and food ingredients, water, and phyto-pharma industries.

Combined, we have over 60 years of professional experience with companies such as Nestlé, Unilever, Quest International, and Campari. When founder Dr Francis Scanlan launched the company in July 2017 we were new to this exciting world of legal cannabis and have invested considerable time and energy in laying a strong foundation of knowledge and expertise leveraging on our core strengths in product development, manufacturing and regulatory compliance. Our credo is that safety, quality, and regulatory compliance are non-negotiable; and our work ethic is to do the right thing right the first time.

Today we have three business divisions:

  • Nutraceuticals;
  • Pharmaceuticals; and
  • Distribution.

VIVA™ Nutraceuticals

Our family of healthy hemp Swiss chocolates

VIVA is our registered trademark for our nutraceutical range of products. As part of the cannabis edibles market segment, chocolate is a very good vector for allowing the consumer to obtain or complement their daily cannabinoid needs. We first developed a premium quality dark Swiss chocolate for the US market containing a natural broad spectrum cannabidiol CBD hemp extract in three flavours: plain dark; orange and ginger; and moringa and mint. Our goal is to combine the healthy virtues of cocoa with hemp and other plants known for their health benefits: ginger is well known for alleviating stomach and intestinal issues, while moringa is considered a wonder plant capable of boosting immunity. Many consumers, including children, take CBD oils daily; so, we wanted to offer a more enjoyable way of achieving the desired therapeutic benefits.

As international legislation is not uniform and interpretations on directives such as the EU’s Novel Foods legislation may vary, we also needed to develop chocolates suitable for marketing in the EU and other countries. We added a dark Swiss Chocolate to our range using Italian cold pressed hemp seed oil. Poor nutrition associated with the western diet is considered a leading cause of chronic inflammation; and hemp seed oil is one of the few vegetable oils which has the perfect 1:3 ratio of Omega-3 to Omega-6 fatty acids: regular consumption will support the body in regaining its ideal balance. Hemp seed oil is also rich in minerals, vitamin E and amino acids and is thought to help with joint function and menstrual cramps. We call this our Superfood VIVA Chocolate; it is available in all three flavours.

Pharmaceuticals

In 2018 the World Health Organization’s Expert Committee on Drugs of Dependence (ECDD) officially recognised that cannabis has medical benefits; and made specific recommendations to the UN Director General for the rescheduling of cannabis and its derivatives under the International Narcotics Convention. The vote is still pending, but this statement from the WHO underscores what patient associations and a growing number of medical doctors, nurses and pharmacists around the world have recognised over the last decades.

The legal framework continues to evolve, with a growing number of jurisdictions legalising the medical use of cannabis. Cannabis-based medicines offer the potential to reduce healthcare costs and generate tax revenues for national budgets. With these drivers supporting the medical use of cannabis, we will undoubtedly see increased activity in biomedical research and the development of new natural drugs. We too are active in this field and are collaborating with experts at the University of Milan, Italy; University of Florida, Gainesville, USA; and the University of Technology in Jamaica, supporting new research in biomedicine.

Glaucoma and asthma

We consider Jamaica to be the modern birthplace of medical cannabis, as it was here in the 1970s that the then-University of the West Indies Professor of Pharmacology Manley West discovered that cannabis has a positive effect on eyesight. Further research in partnership with his colleague in Ophthalmology, Dr Lockhart, produced evidence that cannabis could reduce intraocular pressure and could therefore be used to treat glaucoma. This in turn led to the world’s first cannabis-based prescription drug being approved by the Jamaican Ministry of Health in February 1983. A short time later, Professor West invented a cannabis-based drug for the treatment of asthma.

As Jamaica has a proven pharmacological background and clinical history of approved cannabis medicines, we are working with the Caribbean Institute of Pharmacy Policy, Practice and Research at the University of Technology, College of Health Sciences, to develop medicines for glaucoma, asthma and potentially other health disorders.

Both glaucoma and asthma are amongst the highest and most widespread health issues in the world and are on the rise. In October 2019, the WHO published its first World Report on Vision, which estimated that 2.2 billion people suffer some form of vision impairment; of which approximately 76 million have glaucoma. In some parts of the world, the incidence rate for glaucoma – the world’s second most prevalent single cause of blindness – can be between 1% and 2 % of the population. Surgical interventions have been the focus of most innovation in recent times; and many of the existing drugs on the market have side effects.

Meanwhile, the WHO estimates the current number of people afflicted with asthma worldwide to be 339 million. Asthma cannot be cured, but a programme of prevention and control can alleviate its impact.

Innovation in pain management

Cannabidiol is known for its anti-inflammatory properties and is used in pain management, stress relief, relaxation – in addition, the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved prescription drugs containing CBD for the treatment of rare forms of epilepsy. One of the best ways to introduce cannabinoids into the bloodstream is through the skin, avoiding the gastrointestinal tract and liver where an important percentage of the cannabinoid may not reach its target.

We have a collaboration with experts in nanotechnology whereby the active principal ingredient (API) – in this case, CBD – is encapsulated in a silica sphere and can then be used in the production of a polymeric fibre made into a fine sheet or mat. The mat is then cut into smaller pieces containing a specific amount of the cannabinoid per cm2 and electro-stitched into a transdermal patch holder avoiding the use of adhesives. Inert encapsulated APIs can be mixed, allowing for different formulations and therapies to be developed. Mats can be stacked, thereby delivering the required dosage; and depending on the encapsulation process, delivery can be time-released. This is a very innovative and highly versatile medical device, allowing an efficient high transfer of the active principal into the bloodstream through the skin while leaving no residue on the skin.

Traditional transdermal patches, such as those for opioids, generally achieve a 20% transfer of the API, leaving 80% as waste in the patch. Not only is this an expensive treatment plan for the patient and healthcare system, but it also entails the need for resource-consuming disposal protocols in clinical environments to avoid the illicit recycling of the opioids extracted from the discarded patches. Our patch is zero waste as the mat and API essentially dissolve on the skin.

Community endeavours

We place great importance on our interactions with patients and the medical community. Last year we were able to carry out a successful case study at the glaucoma unit of the University of Catania, Italy; and thanks to the patient association of the Cannabis Social Club in Bolzano, South Tyrol, we were able to organise a presentation by the renowned Jamaican Opthalmologist Dr Hugh Vaughan on the treatment of glaucoma with cannabis at the Bonvicini Clinic. We are very thankful to Dr Vaughan, who shared his wealth of experience of treating patients since the first cannabis medicine was approved in 1983.

Our memberships of the International Association of Cannabinoid Medicines (IACM), the European Industrial Hemp Association (EIHA) and the Swiss Academy of Pharmaceutical Sciences (SAPhS) also allow us to be informed of the latest advances in medical cannabis and therapeutic applications.

We are proud to play our small role in contributing to the potential of cannabis to be one of the most impactful societal changes for this and future generations.

Dr Francis Scanlan
Managing Director
+41 (0)79 616 4000
info@cloud9ch.com
www.facebook.com/groups/2077534272521886
www.instagram.com/cloud9switzerland
www.cloud9switzerland.com

This article is for issue 4 of Medical Cannabis Network. Click here to get your free subscription today.

Subscribe to our newsletter

Source: https://www.healtheuropa.eu/cloud-9-switzerland-group-nutraceuticals-and-pharmaceuticals/103004/

The post Cloud 9 Switzerland Group: nutraceuticals and pharmaceuticals – Health Europa appeared first on CBD Oil For Anxiety Relief.

]]>
Best CBD Gummies for Pain, Stress & Anxiety Relief – Observer https://zenhemp.net/best-cbd-gummies-for-pain-stress-anxiety-relief-observer/?utm_source=rss&utm_medium=rss&utm_campaign=best-cbd-gummies-for-pain-stress-anxiety-relief-observer Fri, 25 Sep 2020 17:24:04 +0000 http://CBMiTWh0dHBzOi8vb2JzZXJ2ZXIuY29tLzIwMjAvMDkvYmVzdC1jYmQtZ3VtbWllcy1mb3ItcGFpbi1zdHJlc3MtYW54aWV0eS1yZWxpZWYv0gFRaHR0cHM6Ly9vYnNlcnZlci5jb20vMjAyMC8wOS9iZXN0LWNiZC1ndW1taWVzLWZvci1wYWluLXN0cmVzcy1hbnhpZXR5LXJlbGllZi9hbXAv CBD gummies are gaining more and more popularity in recent years, and there are many reasons for this. First of all, CBD gummies are tasty. They are also convenient, portable, and discreet, not to mention there is no measuring necessary, making them easy to dose. For both first timers and […]

The post Best CBD Gummies for Pain, Stress & Anxiety Relief – Observer appeared first on CBD Oil For Anxiety Relief.

]]>

839146_Graphics Observer 1_092220

CBD gummies are gaining more and more popularity in recent years, and there are many reasons for this. First of all, CBD gummies are tasty. They are also convenient, portable, and discreet, not to mention there is no measuring necessary, making them easy to dose. For both first timers and experienced CBD users, CBD gummies are a great option.

The research on CBD is still relatively new, but scientific evidence suggests it may provide certain therapeutic benefits. Additionally, CBD users tend to rave about how great it is, so the anecdotal evidence is strong as well. Some of the main reasons people choose to use CBD are relief from anxiety, stress, and pain.

Overall, CBD has been found to be safe to use, but that doesn’t mean there aren’t some risks involved. Those risks come from the fact that over-the-counter CBD products remain unregulated by the FDA. Some CBD companies put profit over quality, which is why it is important to research a CBD gummy brand.

Luckily, we’ve done a bunch of that research for you. All the CBD gummies included in the list below are derived from hemp grown in the US, have been tested by a third-party lab, and have less than 0.3 percent THC, since THC is still not legal federally.

How we chose which CBD gummies to include on this list

The products in this list had to check off each of the items on the following list to ensure our recommendations are safe, high-quality products:

  • Proof of third-party testing by a certified lab
  • Certificate of Analysis (COA) shows no more than 0.3 percent THC, including for full-spectrum products
  • COA shows the product has passed all tests for molds, heavy metals, and pesticides
  • The hemp used to make the product was grown in the US

Other factors in which CBD gummy brands were selected included product potency, product manufacturing process, and brand reputation. A CBD brand can earn a good reputation by getting great customer reviews, not making any unverified health claims, and never receiving a Trusted Source warning letter from the FDA.

Why we love these CBD gummies

Many things can make one CBD product better than another. Pure CBD is an organic compound, meaning that scientifically speaking, it has the same chemical makeup regardless of brand. However, to make CBD gummies, other ingredients must be included as well.

The quality of those other ingredients is a factor in why we love the CBD gummies in the list below. Another element is the price.

Cost

Once a brand’s safety and quality have been adequately verified, CBD gummies’ price starts to matter. After all, if it’s all the same main ingredient, high-quality, US-grown CBD, why should one cost much more than another?

Price can vary based on whether the product is organic and has other desired ingredients and potency. The pricing chart below will help you recognize where each CBD gummy product in the list below ranks in terms of price per potency. 

  •         $ – under $0.10 per mg of CBD
  •         $$ – from $0.10 to $0.20 per mg of CBD
  •         $$$ – over $0.20 per mg of CBD

CBD terms that are helpful to know

  • Full-spectrum CBD is made up of mostly CBD. However, it will also have small quantities of other cannabis plant elements, including other cannabinoids besides CBD (including THC), flavonoids, and terpenes. Full-spectrum CBD is not pure, but some cannabis experts claim it is more effective than pure CBD because all of the plant’s elements work together synergistically.
  • Broad-spectrum CBD is also made up of mostly CBD. However, it also has other cannabinoids, flavonoids, and terpenes from the cannabis plant in very small quantities. The only cannabinoid missing from broad-spectrum CBD is THC, mostly for legal reasons.
  • CBD isolate is pure CBD. All other elements from the cannabis plant have been removed.
  • Flavonoids give all plants their flavor. A tomato tastes like a tomato because of its flavonoids, and different strains of cannabis and hemp have different flavors for their varying flavonoid profiles. Flavonoids can be found in both full and broad-spectrum CBD.
  • Terpenes give all plants their aroma. Most terpenes are said to have health benefits. Cannabis is a plant with a variety of different terpenes depending on the strain. Terpenes can be found in both full and broad-spectrum CBD.

10 of the Best Brands of CBD Gummies on the Market

  1. Calm by Wellness – CBD Gummies

839146_Graphics Observer 2_092220

Price: $$

Calm by Wellness is a CBD brand known by its customers for quality hemp-sourced products that are free of THC, certified non-GMO, and organic. This is what keeps them so loved by their loyal customers. Plus, Calm by Wellness uses broad-spectrum CBD to make sure their products have the advantage of using the whole hemp plant, minus the THC.

Each Calm by Wellness CBD gummy contains 10 mg of CBD and only natural oils and fruit and vegetable extracts. There is no melanin in this calming product, while other similar products do. They are also free harmful ingredients like high-fructose corn syrup, using organic cane sugar to sweeten them. And if that weren’t enough, they also have a vegan version of the gummies, which use pectin instead of animal gelatin.

  1. Joy Organics – Premium CBD Gummies

839146_Graphics Observer 4_092220

Price: $$

The co-founder and CEO of Joy Organics is Joy Smith, a grandmother who searched for support to deal with health issues. That’s when she found CBD and eventually decided to start her own business from this natural substance that helped her so much. Joy wanted to share the love with the world.

Joy Organics has gained customer trust and popularity by using a seven-step process to ensure its quality, including Premium CBD Gummies, which are entirely free of THC, vegan, and gluten. The Premium gummies come in two flavors, Green Apple, or Strawberry Lemonade. With 10 mg of CBD in each gummy, this is a suitable dosage for new CBD users and experienced users alike.

  1. Penguin – CBD Gummy Worms

penguin

Price: $$

Made with pure CBD isolate from hemp grown in Oregon free of chemical fertilizers and pesticides, Penguin CBD Gummy Worms are a product that you can trust to be quality. On top of the product quality also comes some fun, as these gummies are made in the shape of worms and are coated with a sweet-and-sour sugar blend. For any fan of sour candy, these gummy worms should definitely pique your interest.

Each Penguin CBD gummy worm has 10 mg of CBD. This makes it easy to take a relatively low dose or double or triple up for a higher dose. Plus, the company is fully transparent, listing the gummy ingredients right on the website and offering easy-to-read third-party lab results for each different product they sell.

  1. Charlotte’s Web – Calm CBD Gummies

839146_Graphics Observer 9_092220

Price: $

Charlotte’s Web gained a lot of popularity after its products were used for epilepsy. They are still riding that popularity today thanks to the high-quality they continue to deliver. Their Calm CBD Gummies use full-spectrum CBD. While their gummies do contain some THC, it is a trace amount. Their COAs show less than 0.3 percent THC in all products. Using the whole plant to make products also means there are tons of naturally occurring terpenes, flavonoids, and other cannabinoids as well.

Some studies have indicated that two of the terpenes in Charlotte’s Web Calm CBD Gummies,  lemon balm and l-theanine, can be great for mood and relaxing. Charlotte’s Web also uses natural fruit and vegetable juices in their gummies, each of which comes with 10 mg of CBD. And despite the high quality of their gummies, they still make them very affordable.

  1. CBDfx – CBD Gummies with Turmeric & Spirulina

839146_Graphics Observer 6_092220

Price: $$

CBDfx’s CBD Gummies are made with vegan, broad-spectrum CBD. Aside from being made from organic pectin instead of animal gelatin, they also contain all-natural ingredients and no artificial sweeteners. Two of the ingredients in these gummies, turmeric, and spirulina, are superfoods high in antioxidants.

There is evidence that turmeric and spirulina may function as anti-inflammatories, so in combination with the CBD, these gummies may be especially helpful for pain management. Aside from that, CBDfx gummies come from organically farmed hemp, always a plus. One bottle of these gummies includes 60 gummies each with five milligrams of CBD, making them great for beginners.

  1. Fab CBD – CBD Gummies

839146_Graphics Observer 3_092220

Price: $

Fab CBD may be a relatively new company in the world of cannabis, but they have already built a trusting customer base that loves to rave about the quality of their products. Their CBD Gummies are sourced from Colorado-based organic hemp and made from CBD isolate, making them completely THC-free. They are also free of pesticides, solvents, and other harmful contaminants, assured by their COA.

All the other ingredients in their gummies are also top-notch, which are all-natural, free of GMOs, vegan, and gluten-free. Every gummy contains a high dose of 25 mg of CBD and comes in a tasty fruity flavor. The price point of Fab CBD Gummies at only 0.08 cents per mg of CBD makes this product a deal.

  1. Sunday Scaries – CBD Gummies

sunday scaries

Price: $$

Sunday Scaries CBD Gummies are made with broad-spectrum CBD, plus vitamins D-3 and B-12. Some studies have potentially linked low vitamin D as well as low vitamin B-12 to depression, so having vitamin D paired with CBD could be a soothing combination. What’s more, their hemp is sourced from Colorado, where the Sunday Scaries’ owners have visited personally to ensure only high-quality hemp is used in their CBD products.

Sunday Scaries CBD Gummies are made with 10 mg each, which means they are great for both beginners and expert CBD users who might want to double or triple up. The non-vegan version of Sunday Scaries CBD gummies is gelatin-based and use pure-cane sugar. The vegan version contains pectin instead.

  1. Verma Farms – CBD Gummies

839146_Graphics Observer 8_092220

Price: $$

Verma Farms CBD gummies are a US hemp-derived product, organic and grown free of pesticides and GMOs. Each gummy contains a larger dose than many other CBD gummy products with 25 mg. As such, they may not be the ideal gummy choice for beginning CBD users.

These gummies come in various delicious, sweet-sour flavors, including Maui Melon, Peachy Pau Hana, Blueberry Wave, Island Apple, and Berry Beach. Verma Farms is a socially conscious business inspired by the pureness of Maui. All of their products are completely free of THC, making them legal across all 50 states.

  1. Green Roads –  Relax Bears

green roads

Price: $$

Green Roads Relax Bears are made from CBD isolate, derived from non-GMO hemp. Each package contains five gummies, each with 10 mg of CBD. The small quantity of chews in each package makes it easier on the wallet upfront, though a larger bottle is available when you’re ready to commit. Also, each gummy’s low-moderate dose is ideal for dosing, as you can always take more as desired.

Customer reviews often include lots of compliments on the sweet-sour flavor of these gummies, so you can feel confident that you’ll enjoy the process of eating them too. They genuinely seem to be a fan favorite among CBD users between the taste and the quality of these gummies.

  1. Green Gorilla – Gorilla CBD Gummies

green gorilla

Price: $$

Green Gorilla is not only a company with high-quality, organic, 0 percent THC, they are also a fantastic company from an environmental standpoint. They grow their hemp using sustainable practices, meaning no use of chemical fertilizers or pesticides and the use of a natural aquifer to save water. Plus, their soil is rich in nutrients to help preserve water as well.

Each Gorilla CBD gummy has 5 mg of CBD, is soy and nut-free, and kosher as well. They come in three flavors: Strawberry, Wild Berry, and Gorilla Berry. Additional ingredients include organic oils, extra-virgin olive oil, turmeric, and rosemary.

Takeaway

The mounting evidence for CBD’s health benefits, including to help with stress, anxiety, and pain management, makes a strong case for trying out CBD to see if could be the right choice for you.

While more research is needed to confirm CBD’s potential health benefits, the information scientists currently have is promising. Plus, the only safety issue has to do with CBD being unregulated as opposed to the substance itself creating any danger, so that makes it an easier decision to try it out. After all, what’s the harm, especially since the work of investigating brands has already been done here. This excellent selection of CBD gummies comes from all high-quality brands that are known and trusted by their consumers.

This post contains affiliate links. If you purchase products through these links Observer may earn a commission.  

Source: https://observer.com/2020/09/best-cbd-gummies-for-pain-stress-anxiety-relief/

The post Best CBD Gummies for Pain, Stress & Anxiety Relief – Observer appeared first on CBD Oil For Anxiety Relief.

]]>
CEOs to defend prices before House committee – BioWorld Online https://zenhemp.net/ceos-to-defend-prices-before-house-committee-bioworld-online/?utm_source=rss&utm_medium=rss&utm_campaign=ceos-to-defend-prices-before-house-committee-bioworld-online Fri, 25 Sep 2020 16:24:45 +0000 http://CBMiVWh0dHBzOi8vd3d3LmJpb3dvcmxkLmNvbS9hcnRpY2xlcy80OTgxMDMtY2Vvcy10by1kZWZlbmQtcHJpY2VzLWJlZm9yZS1ob3VzZS1jb21taXR0ZWXSAQA Top executives of six biopharma companies will be called to testify before the U.S. House Committee on Oversight and Reform next week to explain their drug pricing strategies. “These companies sell medications that are critical to our health and well-being, but their skyrocketing prices are simply unsustainable,” Rep. Carolyn Maloney, […]

The post CEOs to defend prices before House committee – BioWorld Online appeared first on CBD Oil For Anxiety Relief.

]]>
Top executives of six biopharma companies will be called to testify before the U.S. House Committee on Oversight and Reform next week to explain their drug pricing strategies.

“These companies sell medications that are critical to our health and well-being, but their skyrocketing prices are simply unsustainable,” Rep. Carolyn Maloney, chair of the committee, said in announcing the two-day hearings.

The first day of the hearings, Sept. 30, will feature testimony from former Celgene Corp. CEO Mark Alles, Bristol Myers Squibb (BMS) CEO Giovanni Caforio and Teva Pharmaceutical Industries Ltd. CEO Kåre Schultz. They will be asked about the pricing of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate) and Celgene’s cancer drug Revlimid (lenalidomide). (BMS acquired Celgene last year.)

Then on Oct. 1, Amgen Inc. CEO Robert Bradway, Mallinckrodt Pharmaceuticals CEO Mark Trudeau and Novartis AG’s U.S. Country President Thomas Kendris are scheduled to testify. That hearing will look at the pricing strategies for Amgen’s anti-inflammatory drug Enbrel (etanercept) and chronic kidney disease drug Sensipar (cinacalcet), Mallinckrodt’s autoimmune/inflammatory disease drug H.P. Acthar Gel (repository corticotropin injection) and Novartis’ cancer drug Gleevec (imatinib).

The hearings are part of an investigation the committee launched nearly two years ago into why drug companies continuously increase prices, how they use their profits and what steps can be taken to make U.S. prescription drugs more affordable, Maloney said.

Convalescent plasma trials expand

Two NIH-funded randomized, placebo-controlled trials evaluating convalescent plasma as a treatment for patients hospitalized with COVID-19 are expanding enrollment.

“The evidence on convalescent plasma as a treatment for severe cases of COVID-19 is promising but incomplete. … While the world waits for an effective vaccine, it is vital that we simultaneously expand the options for available treatments for those currently suffering from the worst effects of this disease,” NIH Director Francis Collins said.

Initially launched in April, the trials are enrolling hospitalized patients at academic and community-based hospitals across the country. With the expansion, each trial is expected to enroll about 1,000 hospitalized adults with COVID-19 respiratory symptoms. The trials are receiving $48 million through the government’s Operation Warp Speed program.

CBD public meeting, generics

Having approved GW Pharma plc’s Epidiolex (cannabidiol) in September 2018, the FDA is now issuing a draft guidance on bioequivalence recommendations for a generic cannabidiol (CBD) oral solution.

Comments on the draft guidance should be submitted to Docket No. FDA–2020–D–1640 by Nov. 23, according to a notice posted in the Sept. 23 Federal Register.

The FDA also announced that it will hold a virtual public meeting Nov. 19 on potential sex and gender differences in the use and responses to CBD and other cannabinoids. The meeting will address patient and health care provider perspectives on the use of the products, differences in the effects of the drugs by sex, use of CBD and other cannabinoids in pregnancy, and government agency perspectives on CBD research and evaluation.

ICER updates in CF in MM

The Institute for Clinical and Economic Review (ICER) has released an evidence report assessing the comparative clinical effectiveness and value of Trikafta (elexacaftor/tezacaftor/ivacaftor, Vertex Pharmaceuticals Inc.) for the treatment of cystic fibrosis (CF). It also examined new data that have become available since its May 2018 review of three related CF treatments from Vertex: Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor) and Symdeko (tezacaftor/ivacaftor). Trikafta earned ICER’s highest “A” evidence rating since the drug provides a substantial net health benefit over standard care and over Symdeko. In addition, although Trikafta has not yet been studied in patients who are heterozygous for the F508del mutation and a residual function mutation, ICER determined that using Trikafta to treat that subpopulation is likely to be at least as good as treating with Symdeko, and possibly better. For their respective indicated populations, ICER’s evaluation of new evidence for the three related treatments confirms its previous evidence ratings. The evidence provides high certainty that Kalydeco provides a substantial net health benefit, Orkambi provides a small net health benefit, and Symdeko provides at least a small net health benefit with the potential for a substantial benefit. Kalydeco, Orkambi and Symdeko all meet ICER’s definition of a treatment for an ultra-rare condition. However, due to its broader label and a potential U.S. patient population greater than 10,000 individuals, Trikafta does not meet ICER’s definition as a treatment for an ultra-rare condition. ICER’s recommended health-benefit price benchmark for Trikafta is $67,900 to $85,500 per year, which would require at least a 73% discount off the treatment’s current list price.

ICER has also posted a draft scoping document outlining a planned review of the comparative clinical effectiveness and value of CAR T treatments and a monoclonal antibody drug for multiple myeloma. Comments can be submitted by email to publiccomments@icer-review.org and must be received by 5 p.m. ET on Oct. 13.

Source: https://www.bioworld.com/articles/498103-ceos-to-defend-prices-before-house-committee

The post CEOs to defend prices before House committee – BioWorld Online appeared first on CBD Oil For Anxiety Relief.

]]>
Legalization Efforts Continue to Drive the Cannabis Market Growth – PRNewswire https://zenhemp.net/legalization-efforts-continue-to-drive-the-cannabis-market-growth-prnewswire/?utm_source=rss&utm_medium=rss&utm_campaign=legalization-efforts-continue-to-drive-the-cannabis-market-growth-prnewswire Fri, 25 Sep 2020 16:24:34 +0000 http://CBMieWh0dHBzOi8vd3d3LnBybmV3c3dpcmUuY29tL25ld3MtcmVsZWFzZXMvbGVnYWxpemF0aW9uLWVmZm9ydHMtY29udGludWUtdG8tZHJpdmUtdGhlLWNhbm5hYmlzLW1hcmtldC1ncm93dGgtMzAxMTM4MDI0Lmh0bWzSAQA NEW YORK, Sept. 25, 2020 /PRNewswire/ — The legalization of cannabis in several countries is one of the key factors driving the market’s growth. In addition, the use of cannabis for medical purposes is gaining momentum worldwide. Medical cannabis products are used for the treatment of various chronic conditions such […]

The post Legalization Efforts Continue to Drive the Cannabis Market Growth – PRNewswire appeared first on CBD Oil For Anxiety Relief.

]]>
NEW YORK, Sept. 25, 2020 /PRNewswire/ — The legalization of cannabis in several countries is one of the key factors driving the market’s growth. In addition, the use of cannabis for medical purposes is gaining momentum worldwide. Medical cannabis products are used for the treatment of various chronic conditions such as cancer, arthritis, and neurological conditions, as well as anxiety, depression, epilepsy, as well as Parkinson’s and Alzheimer’s disease. This year, the elections across the country will help determine the future of cannabis products in several states and could have an influence on the federal legalization in the future. According to Leafy, six states will be voting on legalization this November, with four states are voting on adult-use (recreational) cannabis legalization: Arizona, Montana, New Jersey, and South Dakota. Two states are voting on medical marijuana legalization: Mississippi, and South Dakota. Oregon voters will consider two separate drug reform measures. One would legalize the medical use of psilocybin. The other would decriminalize small amounts of all drugs. MediPharm Labs Corp. (OTC: MEDIF) (TSX: LABS), HEXO Corp. (NYSE: HEXO), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), OrganiGram Holdings Inc. (OGI), GW Pharmaceuticals plc (NASDAQ: GWPH)

The increasing popularity of CBD is mainly credited to various medical applications that are associated with the products. Currently, CBD is sonly approved by the U.S. Food and Drug Administration to treat epilepsy. On the other hand, following the de-scheduling of CBD by the U.S. Drug Enforcement Administration last year, more people are using CBD as an over-the-counter medication or treatment. “While there continues to be uncertainty and a healthy amount of confusion around hemp cultivation for CBD production, it is clear that demand is nonetheless continuing to rise across the U.S.,” noted Giadha Aguirre de Carcer, New Frontier Data CEO and Founder. “As states issue more licenses, consumer demand increases, and mass-market retailers such as CVS and Walgreens continue to expand their own product offerings, we expect the FDA may be forced to provide further regulatory clarifications sooner rather than later.”

MediPharm Labs Corp. (OTCQX: MEDIF) (TSX: LABS) announced breaking news earlier this week that, “its wholly owned subsidiary MediPharm Labs Inc. will supply premium, GMP-certified formulated cannabis oil to XLR8 BRAZIL (“XLR8”), a Rio de Janeiro based value-added distributor serving Brazil, Latin America’s largest medical cannabis market.

Under the two-year agreement commencing from the time of product authorization, MediPharm Labs Inc. will provide a variety of cannabis concentrate formats for patient-ready formulated products that will be distributed by XLR8 to leading pharmacies and other authorized channels in Brazil. The initial product SKUS include a 20:1 CBD rich product and a 10:10 balanced THC and CBD formulation. XLR8 will obtain ANVISA Sanitary Product Authorization and undertake the process for final Product Registrations.

“By virtue of its large population, forward-thinking legislative eco-system and economic strength, Brazil is one of the world’s most promising medical cannabis markets and the natural next port of call for our international expansion and growth strategy,” said Pat McCutcheon, CEO of MediPharm Labs. “Given Brazil’s potential as one of our key target markets, we have chosen to partner with XLR8 because of their focus on quality and compliance, their extensive relationships with local healthcare professionals and dedicated focus on the advancement of medical cannabis scientific validation and education. They are the perfect complement to and outlet for our pharma-quality production.”

This is MediPharm Labs’ second distribution agreement in Latin America and evidence of growing international momentum with its strategy of targeting emerging jurisdictions that offer excellent opportunity for sustainable revenue expansion.

“As early participants in the Brazilian medical cannabis industry dating back to its involvement in the pioneering import of medical cannabis oil for patient use from Canada to Brazil in 2017, XLR8 is pleased to have entered into this supply agreement with one of the only PIC/S GMP certified manufacturers of medical cannabis derivatives,” says Mike Dacks of Type 2 Ventures who acts as a strategic advisor to XLR8. “We look forward to bringing these products to market and to working with ANVISA as well as our ecosystem of local partners to bring the required clinical validation for final Product Registrations under the new Brazilian legislative framework.”

“In our view, Brazil is destined to be a global powerhouse in medical cannabis,” said Thiago Callado, Founder and CEO of XLR8. “To make this exciting future a reality, Brazilians need reliable access to formulations that are constructed using proven methodologies that meet the most rigorous international standards of care. By aligning with MediPharm Labs, a company that has GMP certification, the veritable gold seal in pharma-grade production, XLR8 can now begin to fulfill our mission of market leadership.'”

For our latest “Buzz on the Street” Show featuring MediPharm Labs Corp. recent corporate news, please head over to: https://www.youtube.com/watch?v=xzt3VZCUN3I&ab_channel=FinancialBuzzMedia

HEXO Corp. (NYSE: HEXO) reported in July the launch its line of vape products to both adult-use and medical consumers, across Canada. “At HEXO, we pride ourselves in ensuring our consumers have access to high-quality, reliable and consistent cannabis products,” said Sebastien St. Louis, CEO and co-founder of HEXO Corp. “We are thrilled to launch our vape products across Canada as we continue to focus on innovation and launching additional 2.0 products across all of our brands.” Prior to releasing its line of vapes, the Company conducted testing to evaluate the taste, tolerability of effects and short-term undesired effects of its proprietary terpene blends. HEXO’s vape products currently include three ready-to-use vape pens and four 510-thread cartridges, in popular strain-inspired terpene blends.

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) announced last week that the U.S. Food and Drug Administration has granted orphan drug designation for cannabidiol (CBD) for use in treating 22q11.2 deletion syndrome (22q). 22q is a rare midline condition featuring physical abnormalities and debilitating neuropsychiatric and behavioral symptoms including anxiety, withdrawn behavior, and social interaction problems. “Zynerba is committed to developing Zygel™ CBD gel in certain rare and near-rare conditions, including 22q, for which there is an urgent need for new, innovative therapeutics,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “We are pleased that the FDA shares our sense of urgency regarding the development of effective therapeutics in this important patient population. The receipt of this designation represents another important milestone for us, and we look forward to working closely with the FDA to develop Zygel in pediatric and adolescent patients with 22q as expeditiously as possible.”

OrganiGram Holdings Inc. (OGI) the parent company of Organigram Inc. announced back in August that it has partnered with Medical Cannabis by Shoppers™ (“Shoppers”) on Phase 2 of Shoppers’ Pilot Program powered by software partner TruTrace Technologies Inc. The program is designed to genetically finger-print all participating cannabis products, tracking them throughout the supply chain, from genome to patient, in order to provide real-time information about the composition of each cannabis product used by Medical Cannabis by Shoppers customers. Organigram will provide cannabis products to Shoppers for use in the tracking program. “Organigram is proud of our long-standing commitment to our medical cannabis community. From the development of innovative products to the support offered by our patient care team and programs, patients and their needs are at the heart of our medical cannabis business,” says Greg Engel, CEO, Organigram. “We also recognize how critical consistency is to patients and their healthcare providers so are pleased to partner with Shoppers, providing our products so that they can be followed from raw material to finished product, to offer them important, useable product insights.”

GW Pharmaceuticals plc (NASDAQ: GWPH) reported this week that the Australian Therapeutic Goods Administration (TGA) has approved EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older. This represents GW’s cannabis-based medicine’s third global regulatory approval, following US Food and Drug Administration (FDA) approval in 2018 and European Commission (EC) approval in 2019. GW has partnered with Chiesi Australia to make this medicine available in Australia, and the Company will now work alongside its partner and Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) to secure reimbursement for the medicine through a listing on the Pharmaceutical Benefits Scheme (PBS). “GW was founded over two decades ago with a mission to bring cannabis-based medicines to patients with an unmet medical need. We are proud to now be able to bring GW’s cannabidiol to patients in Australia following this approval and our partnership with Chiesi Australia,” said Chris Tovey, GW’s Chief Operating Officer. “This marks our third global regulatory approval and is another important step for GW and the patients we are here to support. The TGA approval is further proof that cannabis-based medicines can successfully go through extensive randomised placebo-controlled trials and a rigorous evaluation process to reach patients who need them.”

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com 

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.financialbuzz.com  (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For medipharm labs corp., video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

Media Contact:

[email protected]

+1-877-601-1879

www.FinancialBuzz.com

SOURCE FinancialBuzz.com

Source: https://www.prnewswire.com/news-releases/legalization-efforts-continue-to-drive-the-cannabis-market-growth-301138024.html

The post Legalization Efforts Continue to Drive the Cannabis Market Growth – PRNewswire appeared first on CBD Oil For Anxiety Relief.

]]>
Legality of use of CBD Oil in India, and why NDPS Act does not apply to it – Lexology https://zenhemp.net/legality-of-use-of-cbd-oil-in-india-and-why-ndps-act-does-not-apply-to-it-lexology/?utm_source=rss&utm_medium=rss&utm_campaign=legality-of-use-of-cbd-oil-in-india-and-why-ndps-act-does-not-apply-to-it-lexology Fri, 25 Sep 2020 16:04:03 +0000 http://CBMiU2h0dHBzOi8vd3d3LmxleG9sb2d5LmNvbS9saWJyYXJ5L2RldGFpbC5hc3B4P2c9ZDA1NTJjZjQtNmQwNS00NzRiLTkyM2YtNjgxZWU4Njk0YmEx0gEA Recreational use of Cannabis (Ganja) and its resin (Charas or Hashish) was outlawed in India in 1985 by the Narcotic Drugs and Psychotropic Substances Act, 1985 (“NDPS Act”). The NDPS Act itself was the result of India’s commitment under the Single Convention on Narcotic Drugs, 1961 (“Single Convention”). Interestingly, neither […]

The post Legality of use of CBD Oil in India, and why NDPS Act does not apply to it – Lexology appeared first on CBD Oil For Anxiety Relief.

]]>

Recreational use of Cannabis (Ganja) and its resin (Charas or Hashish) was outlawed in India in 1985 by the Narcotic Drugs and Psychotropic Substances Act, 1985 (“NDPS Act”). The NDPS Act itself was the result of India’s commitment under the Single Convention on Narcotic Drugs, 1961 (“Single Convention”). Interestingly, neither the NDPS Act nor the Single Convention outlawed the medical use of cannabis. Nevertheless, medical use of cannabis is almost non-existent in India.

The ground reality is that most State Governments in India are reluctant to issue a license to cultivate and grow cannabis, even though the NDPS Act empowers them to do so. Therefore, almost all cannabis that manufacturers of cannabis-based medicines have access to grows in the wild. Because the cannabis plant grows in the wild with little to no human intervention, there is very little scope for quality control and standardization of the cannabis, which is essential to manufacture a cannabis-based medicine. This poses a big challenge for manufacturers and discourages them from manufacturing cannabis-based medicines at a meaningful scale.

The NDPS Act, however, does not apply to the leaves and seeds of cannabis plant when they are separated from the flowering or fruiting tops of the plant, which are its most intoxicating parts. This is why Bhang (cannabis plant leaf) is sold freely in most States in India, subject of course to Excise Control, since it is still an intoxicant.

As the leaves of cannabis plant are relatively easy to access, there is massive potential for its use in medicine. One of the key chemicals (or cannabinoids) present in cannabis, including in its leaves, is CBD or Cannabidiol. CBD possesses medicinal properties, but not narcotic properties. The World Health Organization (WHO) itself has recommended its exclusion from Single Convention because it “does not have psychoactive properties and has no potential for abuse and no potential to produce dependence.

Most CBD Oils sold in India (including over internet) are in fact made out of full-spectrum extracts of the leaves of the cannabis plant, meaning they contain all the cannabinoids, including CBD, that are present in the leaves. Since the leaves of cannabis plant are not considered to be a narcotic drug, CBD Oil made out of extract of the leaves should also not be treated as narcotic drug. In other words, consumption of CBD Oil manufactured from leaves of the cannabis plant should not attract provisions of the NDPS Act.

In fact, CBD Oil manufactured under a license issued under the Drugs and Cosmetics Act, 1940 may be legitimately used by individuals for medical purposes in India.

It is easy to confuse CBD oil with cannabis or hash oil, but the two are vastly different, both in terms of pharmacology and legal treatment: cannabis or hash oil, unlike CBD oil, is 100% narcotic and is subject to strict monitoring and control in India as per provisions of NDPS Act. Its consumption may also attract provisions of NDPS Act and may result in imprisonment.

Source: https://www.lexology.com/library/detail.aspx?g=d0552cf4-6d05-474b-923f-681ee8694ba1

The post Legality of use of CBD Oil in India, and why NDPS Act does not apply to it – Lexology appeared first on CBD Oil For Anxiety Relief.

]]>
CBD Oil for Sleep: The All Natural Sleep Aid Everyone is Talking About – The Daily Dot https://zenhemp.net/cbd-oil-for-sleep-the-all-natural-sleep-aid-everyone-is-talking-about-the-daily-dot/?utm_source=rss&utm_medium=rss&utm_campaign=cbd-oil-for-sleep-the-all-natural-sleep-aid-everyone-is-talking-about-the-daily-dot Fri, 25 Sep 2020 15:54:18 +0000 http://CBMiOGh0dHBzOi8vd3d3LmRhaWx5ZG90LmNvbS9pcmwvYmVzdC1jYmQtb2lsLWZvci1zbGVlcC1haWQv0gEA If you suffer from insomnia, PTSD, or other rest-inhibiting disorders, it’s likely that someone you know has recommended you try CBD oil to help you sleep. But not all CBD products are alike. Before you grab the first one you see off the shelves, read our guide to learn which […]

The post CBD Oil for Sleep: The All Natural Sleep Aid Everyone is Talking About – The Daily Dot appeared first on CBD Oil For Anxiety Relief.

]]>

If you suffer from insomnia, PTSD, or other rest-inhibiting disorders, it’s likely that someone you know has recommended you try CBD oil to help you sleep. But not all CBD products are alike. Before you grab the first one you see off the shelves, read our guide to learn which ones are the best fit for you.

Advertisement Hide

What is CBD?

Cannabidiol (CBD) is one of the main chemical components (or cannabinoids) found in the Cannabis sativa plant. Unlike THC (another cannabinoid), CBD is not psychoactive. Meaning, it won’t get you high or alter your perception and it can be harvested for agricultural purposes via the hemp plant.

Advertisement Hide

How does CBD help you sleep?

Its effects, according to the British Pharmacological Society Journals, can help relieve a wide range of symptoms including those associated with mood disorders, chronic pain, anxiety, seizures, and insomnia. However, since most CBD products are listed as supplements or all-natural sleep aids (versus medications), both the products themselves and their effects have not been regulated or substantiated by the FDA. 

But how does CBD help you sleep? I’m getting to that.

Remember how I mentioned CBD belongs to a group of cannabinoids found in hemp and marijuana plants? This is important because it makes CBD one of many chemical compounds that interact with our endocannabinoid systems, triggering one of two receptors: CB1 or CB2. Since our focus is on CBD (and not CBG, CBA, CBN, etc.), I’m only going to focus on the affected antenna–our Cannabinoid Type 1 (CB1) receptor.

Advertisement Hide

CB1 receptors are found all over the body, more importantly, they’re a prominent subtype of the central nervous system (AKA our brain and spinal cord). Because of where the majority of these receptors are located, it’s safe for you to assume that they play some sort of role in regulating mood, thought pattern, and other synaptic transmissions (or information sharing processes).

Advertisement Hide

Usually, assumptions are the wrong move but in this case, it’s alright because studies have actually linked the activation of CB1 receptors to both “short-term and long-term changes in the efficacy of synaptic transmission.” In plain English, this means that trials have shown triggering CB1 receptors proves to be an effective treatment for both short-term and long-term changes in behavioral patterns caused by internal factors (psychological disorders, metabolism issues, you get the idea).

Now, you’re probably wondering how this connects to your poor sleep cycle. Well, The National Sleep Foundation reports that among the many factors that can contribute to restlessness and insomnia, anxiety, depression, and chronic pain are among the most common causes. I could let you connect the dots, but for accuracy’s sake, I’ll just tell you that these are great examples of “internal behavioral patterns” that have the potential to be corrected by consistent CBD use (researchers suggest taking CBD at least one hour before bed so it has time to take effect). User trials have also suggested that unlike other sleep aids and pain medication, taking the correct dosage of CBD won’t leave you in a haze the next morning.

(Disclaimer: it’s important for you to speak with your doctor before consuming any CBD products, as CBD is known to interfere with certain medications and if you’re pregnant or breastfeeding the FDA advises against the use of any hemp or marijuana products).

Advertisement Hide

What’s the correct CBD oil dosage for sleep?

Like most things in life, this can vary person-to-person depending on a variety of factors (weight, tolerance level, how you’re consuming the CBD, the specific benefits you are seeking, etc.). However, most reputable CBD companies will provide you with a recommended dosage. And like weed edibles, the effects of consuming CBD edibles aren’t immediate so it’s suggested that you wait at least six hours before re-dosing (or upping your dose). Otherwise, you may feel the effects of both doses at once or feel groggy upon waking up.

Best CBD for sleep and where to buy it

If you’ve left your house or turned on your TV in the last few weeks, you may have noticed that everyone from vape and smoke shops to hairdressers and boutique retailers are pushing CBD products. This doesn’t mean you should buy it from them, no matter how “great” they say the products are. Because at the end of the day, this isn’t a regulated industry. And there actually have been instances where companies have falsified how much CBD is actually in the products, attempting to get away with using synthetics and even going as far as adding obscene amounts of melatonin to CBD edibles so consumers “feel” something. All of this is gross and potentially dangerous, so I’m going to tell you how to avoid it: READ THE LAB REPORTS AND INGREDIENT LABELS. I cannot stress this enough, and any reputable company will provide third-party lab results for all its CBD products. Why third-party? Because outside, unrelated labs have nothing to gain from their conclusions. This ensures that the accuracy of the data they provide is never compromised.

So to help you stay out of harm’s way, listed below are a few of my top picks that adhere to strict ethical and safety standards. You can find most of these products online, but if for some reason they’re unavailable or you want to shop local, I suggest stopping at the CBD dispensary near you (yes, those exist) and see what the person behind the counter there would recommend.

Advertisement Hide

1) Medterra CBD

Available online and at participating retailers, Medterra CBD is one of the most well-known and trusted brands in the space. All Medterra products are third-party lab tested and so high in quality, Medterra actually works in partnership with the Hemp Pilot Research Program.

Advertisement Hide

Medterra offers all sorts of CBD products, including broad-spectrum and CBD products for pets. For those looking to order online, the site offers free shipping on orders $99+ and 15% off for those who choose the subscription option.

Best product for promoting sleep: CBD + Melatonin capsules ($55.99)

Advertisement Hide


2) JustCBD

Advertisement Hide

JustCBD is another great online CBD retailer. JustCBD offers more of a variety than Medterra, so if you want to try CBD in all of its forms this is definitely the place to go. The company also does third-party lab tests for all its products, blogs recipe ideas, and regularly runs sales. Online customers can take advantage of free shipping and score 20% off their first order!

Best product for promoting sleep: JustCBD Watermelon Gummies (on sale for $32.50, regularly $40)

Advertisement Hide


3) Extract Labs

Advertisement Hide

The madmen behind Extract Labs’ are actually a key reason this stuff works so well. Instead of formulating with heat (like traditional processes call for), the developers whip all their simple and natural ingredients together. By doing so, Extract Labs’ products are able to retain more of the helpful and highly sought-after compounds the hemp plant is known for.

Best product for promoting sleep: Sleep CBD Bath Bomb ($16), Grandaddy Purp or G-Rilla CBD Shatter ($45 each)

Advertisement Hide


4) Select CBD

Advertisement Hide

Select CBD is my go-to for CBD tincture because it’s one of the few brands that not only nailed the flavor but the consistency of the drops, too! Which is a big deal for anyone who’s tried tincture before, as you probably know just how hard it can be to find a product that won’t make you gag.

Select CBD is not for sale online and can only be purchased at participating retailers, so yeah, you’ll have to leave your house to get your hands on it, but it’s well worth the extra effort!

Best product for promoting sleep: Lavender or Peppermint CBD Tincture drops or Rest CBD Gel Capsules (not available online, prices vary by retailer)

Advertisement Hide

The Daily Dot may receive a payment in connection with purchases of products or services featured in this article. Click here to learn more.

Source: https://www.dailydot.com/irl/best-cbd-oil-for-sleep-aid/

The post CBD Oil for Sleep: The All Natural Sleep Aid Everyone is Talking About – The Daily Dot appeared first on CBD Oil For Anxiety Relief.

]]>
CBD OIL BENEFITS + what it did to my skin! [VIDEO] – plantsbeforepills.com https://zenhemp.net/cbd-oil-benefits-what-it-did-to-my-skin-video-plantsbeforepills-com/?utm_source=rss&utm_medium=rss&utm_campaign=cbd-oil-benefits-what-it-did-to-my-skin-video-plantsbeforepills-com Fri, 25 Sep 2020 15:54:08 +0000 http://CBMiTGh0dHBzOi8vcGxhbnRzYmVmb3JlcGlsbHMuY29tL2NiZC1vaWwtYmVuZWZpdHMtd2hhdC1pdC1kaWQtdG8tbXktc2tpbi12aWRlby_SAQA Over the years, research has shown that cannabidiol is one of the highly medicinal compounds found in the cannabis plant. In fact, products infused with CBD extract is allowed in almost all 50 states in the US with different restrictions on cannabinoid content depending on state laws. Because of this, […]

The post CBD OIL BENEFITS + what it did to my skin! [VIDEO] – plantsbeforepills.com appeared first on CBD Oil For Anxiety Relief.

]]>
Over the years, research has shown that cannabidiol is one of the highly medicinal compounds found in the cannabis plant. In fact, products infused with CBD extract is allowed in almost all 50 states in the US with different restrictions on cannabinoid content depending on state laws. Because of this, more and more people can try out such products and see the results themselves.

One of the most popular types of CBD-infused product is in topical form. This makes it easy to use to treat skin-related conditions such as eczema. If you have eczema, then you may be wondering whether CBD can help improve your condition. Here’s what you need to know:

What is Eczema?

Before we talk about the effects of cannabidiol on individuals with this condition, it is important to discuss what exactly eczema is and what causes it. As you know, the term eczema refers to a group of skin conditions characterized by itchiness, inflammation, swelling, dryness and sensitivity, oozing, change in texture and a rash-like appearance.

The thing about this condition is that it is common, with more than 31 million Americans have one of the seven types. You can develop some form of this skin issue at different stages in your life, from childhood to adulthood, ranging in degree from mild to severe. While this condition is not communicable, there is no cure for it, but you can definitely treat it.

How CBD Can Help Relieve Eczema

Eczema Treatment depends on the cause and severity of the condition. Some remedies include over-the-counter medications, prescription topicals, immunosuppressants, biologic drugs and phototherapy.

As mentioned, no cure has been found for eczema, so do not expect these products to heal your condition. What it can do, however, is to help alleviate the symptoms using topical CBD such as lotions, balms, creams oils. Want to know why cannabidiol can do so? Check out this list.

  • Applying CBD on the affected area will help reduce swelling.

One of the most known attributes of cannabidiol is that it can relieve inflammation. The thing about cannabinoids is that they interact with the body through an internal system dedicated to cannabinoids.

This system is called the endocannabinoid system. It is responsible for releasing and utilizing endocannabinoids. Cannabinoids from cannabis work well with this system. It can relieve inflammation by attaching itself to receptors located in the immune system. Cannabidiol is such a great anti-inflammatory that it is prescribed to epilepsy patients.

  • It Can Relieve Pain and Itchiness

Aside from inflammation, pain and itchiness often come during eczema attacks. This can be caused by the inflammation, but sometimes, extreme dryness of the infected site can also be the culprit. This is a great way to hit two birds with one stone, as they say. You can apply topicals to relieve such sensations, while also addressing the inflammation.

  • It Can Hydrate Your Skin

What’s better than hitting two birds with one stone? Hitting three with one shot, of course! Using topicals to treat inflammation, pain and itchiness can also help address the dryness of your skin. This is because CBD has a hydrating effect.

You should know that CBD has a regulating property, which means that if your skin is dry, the compound can rehydrate it, and if it is oily, CBD can help tone down the sebum production.

Conclusion

Cannabidiol may not be able to entirely rid your skin of eczema, but it can definitely help alleviate the situation. So, if you are looking for ways to address your symptoms, you should buy CBD oil and other infused products.

Source: https://plantsbeforepills.com/cbd-oil-benefits-what-it-did-to-my-skin-video/

The post CBD OIL BENEFITS + what it did to my skin! [VIDEO] – plantsbeforepills.com appeared first on CBD Oil For Anxiety Relief.

]]>